Tay Salimullah is Managing General Partner of Renovamen Advisors and a Venture Partner at 4BIO Capital, supporting early-stage biotech and investor teams at the intersection of scientific innovation and commercial execution. A former executive at Novartis Gene Therapies, Tay helped transform AveXis into a global leader in advanced therapies, pioneering the commercial model for Zolgensma^®– approved in 50+ countries, with over 4,000 patients treated and $5B+ in cumulative revenue. He previously held a variety of investment and healthcare roles, including a decade at Pfizer in strategic and commercial roles. Tay currently serves as Chief Strategy Officer and Board member at Trogenix^®, advancing AAV-based oncology gene therapies. Also, as Executive in Residence at the Alliance for Regenerative Medicine, he brings deep expertise in rare disease, gene therapy, and global commercialization. He holds a BSc in Business Management from Brunel University, London, and completed executive education in Venture Capital at Imperial College London.